Biogen

BIIBNASDAQ

Neurology-focused biologics and small-molecule development platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for BIIB yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

Salanersen SMA 15-60y: Salanersen (BIIB115) in Spinal muscular atrophy, ages 15-60 — primary completion

2028-06-23

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Salanersen presymptomatic infants: Salanersen (BIIB115) in Presymptomatic spinal muscular atrophy — primary completion

2028-11-28

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Salanersen post-onasemnogene: Salanersen (BIIB115) in SMA after onasemnogene abeparvovec — primary completion

2029-07-27

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
LeqembiAlzheimer diseaseApprovedNot disclosed▼
Zurzuvaepostpartum depressionApprovedNot disclosed▼
BIIB080tau-targeting therapy for Alzheimer diseasePhase 2Not disclosed▼

Analysis

We have not yet written an analysis of Biogen that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade BIIB commission-free on Webullvia Webull · Affiliate

Comparable companies

RocheEisaiSage Therapeutics

Sponsored

Get premium BIIB analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Biogen has 205 Phase 2 or 3 studies on ClinicalTrials.gov: 119 completed, 66 stopped early, 20 ongoing.

119

Completed

66

Stopped early

20

Ongoing

Stopped early

  • DAISYPhase 2 · started 2024 · withdrawn

    BIIB131 in ischemic stroke · n=0

    Reason given: Sponsor decision

  • CYPRESSPhase 2 · started 2023 · terminated

    RTA 901 in diabetic peripheral neuropathic pain · n=209

    Reason given: Sponsor decision to close study early; not due to safety concerns.

  • SURGE-1Phase 3 · started 2023 · withdrawn

    BIIB074 in trigeminal neuralgia · n=0

    Reason given: Sponsor Decision

  • SURGE-2Phase 3 · started 2023 · withdrawn

    BIIB074 in trigeminal neuralgia · n=0

    Reason given: Sponsor Decision

  • LIGHTHOUSEPhase 3 · started 2022 · terminated

    BIIB122 in parkinson disease · n=7

    Reason given: Sponsor Decision

  • ENVISIONPhase 3 · started 2022 · terminated

    Aducanumab in alzheimer's disease · n=1027

    Reason given: Sponsor's Decision

  • NCT05265728Phase 3 · started 2022 · terminated

    Natalizumab in multiple sclerosis, relapsing-remitting · n=21

    Reason given: Due to sponsor decision, not for efficacy or safety reasons.

  • NCT04079088Phase 2 · started 2021 · withdrawn

    Placebo in relapsing multiple sclerosis · n=0

    Reason given: Decision to discontinue BIIB061 program was based on lack of stronger preclinical effects of BIIB061 on remyelination relative to opicinumab, that showed limited clinical efficacy in phase 2 clinical studies. This was not related to safety concerns.

  • ALSpirePhase 1/2 · started 2020 · terminated

    BIIB105 in amyotrophic lateral sclerosis · n=99

    Reason given: Sponsor's decision

  • NCT04241068Phase 3 · started 2020 · terminated

    Aducanumab in alzheimer's disease · n=1696

    Reason given: Sponsor's Decision

  • NCT04007367Phase 3 · started 2019 · terminated

    SAGE-217 in major depressive disorder · n=53

    Reason given: Internal company decision

  • FALCONPhase 3 · started 2019 · terminated

    Bardoxolone methyl oral capsule in autosomal dominant polycystic kidney · n=667

    Reason given: Discontinuation of all bardoxolone chronic kidney disease programs

  • NCT03870763Phase 3 · started 2019 · terminated

    Dimethyl Fumarate in multiple sclerosis, relapsing-remitting · n=11

    Reason given: Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns.

  • EAGLEPhase 3 · started 2019 · terminated

    Bardoxolone methyl in chronic kidney diseases · n=270

    Reason given: Discontinuation of all bardoxolone chronic kidney disease programs

  • NCT03771664Phase 3 · started 2019 · terminated

    SAGE-217 in major depressive disorder · n=87

    Reason given: internal company decision

  • EVOLVEPhase 2 · started 2018 · terminated

    Aducanumab in cognitive dysfunction · n=52

    Reason given: Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.

  • SPIRITPhase 2 · started 2018 · terminated

    BG00011 in idiopathic pulmonary fibrosis · n=109

    Reason given: Study was stopped because of safety concerns.

  • NCT03339336Phase 2 · started 2018 · terminated

    BIIB074 in small fiber neuropathy · n=265

    Reason given: Sponsor decision to close study early; not due to safety concerns

  • TANGOPhase 2 · started 2018 · terminated

    BIIB092 in alzheimer's disease · n=654

    Reason given: The study (NCT03352557) was terminated based on lack of efficacy following the placebo-controlled period readout.

  • SPARKPhase 2 · started 2018 · terminated

    Placebo in parkinson's disease · n=357

    Reason given: SPARK did not meet it's primary outcome measure for year 1 and failed to meet secondary outcome measures resulting in the development of BIIB054 (cinpanemab) for Parkinson's disease to be discontinued and SPARK study was closed.

  • AFFINITYPhase 2 · started 2017 · terminated

    BIIB033 (opicinumab) in multiple sclerosis · n=263

    Reason given: The top-line results from the Part 1 did not meet the pre-specified primary endpoint nor the key secondary endpoints. The decision to discontinue study 215MS202 Part 2 was not based on safety concerns.

  • PASSPORTPhase 2 · started 2017 · terminated

    BIIB092 in supranuclear palsy, progressive · n=490

    Reason given: 251PP301(PASSPORT) primary endpoint was not met;Biogen decision to close the study early. There were no safety concerns with the PASSPORT study.

  • SUSTAINPhase 3 · started 2017 · terminated

    Daclizumab in relapsing-remitting multiple sclerosis (rrms) · n=41

    Reason given: Study terminated in line with Biogen decision to withdraw Zinbryta from the market and not to pursue further studies of daclizumab in MS.

  • RANGERPhase 3 · started 2017 · terminated

    Bardoxolone methyl in pulmonary hypertension · n=261

    Reason given: The company determined that continued exposure of these high-risk PH patients to clinic or in-person visits during the COVID pandemic presented an unacceptable risk.

  • RELAY-1 ExtendPhase 2 · started 2017 · terminated

    BIIB074 in neuropathic pain from lumbosacral radiculopathy · n=302

    Reason given: The parent study did not meet its primary or secondary efficacy endpoints and therefore Sponsor decision to discontinue development in this indication.

  • NCT02657356Phase 3 · started 2016 · terminated

    Placebo capsules in connective tissue disease-associated pulmonary arterial hypertension · n=202

    Reason given: Exposure of these high-risk patients to clinic or in-person visits during the pandemic presented an unacceptable risk to their health

  • NCT02855411Phase 2 · started 2016 · terminated

    PF-04958242 in cognitive impairment associated with schizophrenia (cias) · n=35

    Reason given: Terminated prematurely Sept 22, 2016 following an internal portfolio prioritization. It is not due to any safety concern or change in benefit:risk assessment.

  • NCT02428218Phase 3 · started 2016 · withdrawn

    dimethyl fumarate in relapsing-remitting multiple sclerosis · n=0

    Reason given: Feasibility

  • EMERGEPhase 3 · started 2015 · terminated

    Aducanumab (BIIB037) in alzheimer's disease · n=1643

    Reason given: Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed

  • EMBRACEPhase 2 · started 2015 · terminated

    Nusinersen in spinal muscular atrophy · n=21

    Reason given: The study was terminated early to roll over participants to open label extension study NCT02594124.

  • ENGAGEPhase 3 · started 2015 · terminated

    Aducanumab (BIIB037) in alzheimer's disease · n=1653

    Reason given: Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed

  • INSPIREPhase 3 · started 2015 · terminated

    dimethyl fumarate in multiple sclerosis, secondary progressive · n=58

    Reason given: Sponsor Decision

  • TITRATIONPhase 3 · started 2015 · terminated

    dimethyl fumarate in multiple sclerosis · n=62

    Reason given: Sponsor decision

  • SIMPLIFYPhase 2 · started 2014 · terminated

    natalizumab in relapsing multiple sclerosis · n=2

    Reason given: Sponsor's decision.

  • ENDEARPhase 3 · started 2014 · terminated

    nusinersen in spinal muscular atrophy · n=122

    Reason given: After a positive interim analysis, the decision was made to terminate the study early to allow for participants to enroll into an open label study

  • NCT01930890Phase 2 · started 2013 · terminated

    BIIB023 in lupus nephritis · n=87

    Reason given: Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate sufficient efficacy to warrant continuation of the study

  • EXTENDPhase 3 · started 2013 · terminated

    BIIB019 (Daclizumab) in relapsing-remitting multiple sclerosis · n=1501

    Reason given: Study terminated because of differences in the participant population under study compared with indicated Zinbryta use in most countries.

  • NCT01655186Phase 2 · started 2012 · withdrawn

    Bardoxolone Methyl in renal insufficiency, chronic · n=0

    Reason given: IDMC recommendation for safety concerns

  • EMBRACEPhase 2 · started 2012 · withdrawn

    BIIB057 in rheumatoid arthritis · n=0

    No reason recorded in the registry.

  • NCT01576887Phase 2 · started 2012 · withdrawn

    Bardoxolone Methyl 20 mg in end-stage renal disease · n=0

    Reason given: IDMC recommendation for safety concerns

  • ATLASPhase 2 · started 2012 · terminated

    BIIB023 in lupus nephritis · n=276

    Reason given: Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.

  • ASCEND in SPMSPhase 3 · started 2011 · terminated

    natalizumab in secondary progressive multiple sclerosis · n=889

    Reason given: The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.

  • BEACONPhase 3 · started 2011 · terminated

    Placebo in renal insufficiency, chronic · n=2185

    Reason given: IDMC recommendation for safety concerns

  • NCT01181089Phase 1/2 · started 2010 · withdrawn

    Placebo in secondary progressive multiple sclerosis · n=0

    No reason recorded in the registry.

  • SURPASSPhase 3 · started 2010 · terminated

    BG00002 (natalizumab) in relapsing remitting multiple sclerosis · n=84

    Reason given: Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.

  • POSEIDONPhase 2 · started 2009 · terminated

    Tonapofylline in renal insufficiency · n=34

    Reason given: Company Decision

  • NCT00746941Phase 1/2 · started 2009 · terminated

    mefloquine in progressive multifocal leukoencephalopathy · n=37

    Reason given: Primary endpoint not achieved

  • NCT00784836Phase 3 · started 2008 · terminated

    BG9418 (interferon beta 1-a) in multiple sclerosis · n=3

    Reason given: Terminated early by Sponsor for business reasons unrelated to safety.

  • NCT00675428Phase 1/2 · started 2008 · terminated

    BG00002 (natalizumab) in multiple myeloma · n=6

    Reason given: Sponsor decision due to low enrollment and not safety concerns.

  • NCT00801060Phase 2 · started 2008 · terminated

    Lumiliximab + FCR in chronic lymphocytic leukemia · n=40

    No reason recorded in the registry.

  • NCT00384150Phase 3 · started 2007 · terminated

    galiximab in combination with rituximab in lymphoma, non-hodgkin's · n=16

    Reason given: Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.

  • RESPOND-EXTPhase 2 · started 2007 · terminated

    Baminercept alfa (BG9924) in rheumatoid arthritis · n=339

    Reason given: Analysis of data from 104RA202 failed to meet primary endpoint

  • NCT00538343Phase 2 · started 2007 · terminated

    berubicin hydrochloride (RTA 744) in brain metastases · n=14

    Reason given: Business Decision

  • NCT00523328Phase 2 · started 2007 · terminated

    BG9924 in rheumatoid arthritis · n=72

    Reason given: Analysis of data from 104RA203 failed to meet primary endpoint.

  • NCT00550849Phase 1/2 · started 2007 · terminated

    RTA 402 in liver disease · n=16

    Reason given: Enrollment discontinued after second cohort completed.

  • NCT00458861Phase 2 · started 2007 · terminated

    BG9924 in rheumatoid arthritis · n=115

    Reason given: Interim analysis of data failed to meet primary endpoint.

  • LUCIDPhase 2 · started 2006 · terminated

    FCR + Lumiliximab in chronic lymphocytic leukemia · n=627

    No reason recorded in the registry.

  • NCT00363636Phase 3 · started 2006 · terminated

    Galiximab in combination with rituximab in lymphoma, non-hodgkin's · n=340

    Reason given: Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.

  • NCT00298272Phase 2 · started 2006 · terminated

    IDEC-C2B8 (rituximab) in rheumatoid arthritis · n=54

    Reason given: Sponsor decided to end long term extension phase for business reasons unrelated to safety.

  • STRATAPhase 3 · started 2006 · terminated

    Natalizumab in relapsing-remitting multiple sclerosis · n=1094

    No reason recorded in the registry.

  • NCT00102024Phase 1/2 · started 2005 · terminated

    Unconjugated IDEC-159 in colorectal cancer · n=30

    No reason recorded in the registry.

  • NCT00831649Phase 2 · started 2004 · terminated

    natalizumab in rheumatoid arthritis

    Reason given: The biological effect seen with natalizumab was not sufficient to warrant further development in RA.

  • NCT00083759Phase 2 · started 2004 · terminated

    natalizumab in rheumatoid arthritis · n=299

    Reason given: The biological effect seen with natalizumab was not sufficient to warrant further development in RA.

  • NCT00057343Phase 3 · started 2003 · terminated

    Zevalin (ibritumomab tiuxetan) in non-hodgkin's lymphoma · n=400

    No reason recorded in the registry.

  • NCT00535314Phase 2 · started — · withdrawn

    RTA 402 Dose1 in malignant melanoma · n=0

    No reason recorded in the registry.

  • NCT00451815Phase 2 · started — · withdrawn

    active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. in parkinson's disease · n=0

    No reason recorded in the registry.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.